DUBLIN--(BUSINESS WIRE)--The "COVID-19 Vaccine and Therapeutics Pipeline Analysis 2020" report has been added to ResearchAndMarkets.com's offering.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider COVID-19 vaccine & therapeutics pipeline analysis 2020 market, and compares it with other markets.
Major players in the COVID-19 vaccine and therapeutics pipeline analysis market are CanSino Biologics, Moderna, Inovio Pharmaceuticals, Regeneron, Gilead Sciences, GlaxoSmithKline, Medicago Inc., Sanofi, University of Oxford, and Altimmune.
The COVID-19 vaccine and therapeutics pipeline analysis market covered in this report is segmented by product type into small molecules, biologics, blood & plasma derivatives, monoclonal antibodies, vaccines, others. It is also segmented by the phase of development into preclinical therapeutics & vaccines, clinical studies, by treatment mechanism & route of administration, and by type of sponsor into pharma/biotech company, academic research/institution, others.
The COVID-19 vaccine and therapeutics pipeline analysis market report provides an analysis of the coronavirus (COVID-19) therapeutics and vaccines under development. The report includes existing vaccines developed against MERS-CoV and SARS-CoV. The novel coronavirus-2019 (nCoV-19) has been named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses (ICTV) due to its genetic similarity with the coronavirus responsible for the 2003 SARS outbreak. Currently, government agencies, international health authorities and institutions and biopharmaceutical companies worldwide are focusing on developing vaccines/drugs to prevent or treat the COVID-19 infection.
Ever since the coronavirus hit the world as a global pandemic, many key vaccine developers are collaborating to develop potential COVID-19 vaccine against coronavirus.
Most recently, on 21st May 2020, CanSino Biologics Inc. and Precision NanoSystems announced a co-development agreement of an mRNA lipid nanoparticle (mRNA-LNP) vaccine against COVID-19. The parties will leverage Precision NanoSystems's proprietary RNA vaccine platform, comprising of lipid nanoparticle delivery system and the NanoAssemblr manufacturing technology, to rapidly advance a COVID-19 mRNA-LNP vaccine candidate towards human clinical testing and pursuant to regulatory approvals, and commercialization in different regions. Precision NanoSystems will be responsible for the development of the mRNA-LNP vaccine and CanSinoBIO will be responsible for pre-clinical testing, human clinical trials, regulatory approval and commercialization.
Similarly, on May 19, 2020, IPharmaJet, the maker of innovative, needle-free injection technology announced that its Needle-free Injection System technology will be used to deliver a messenger RNA (mRNA) vaccine against SARS-CoV-2. The vaccine is being developed by Abnova Corporation, the world's largest antibody manufacturer, based in Taiwan.
The development of potential drugs and vaccines for COVID-19 is progressing quickly. There is a massive increase in COVID-19 drugs and vaccines pipeline owing to the urgent need to contain the spread of disease. Government agencies, global health authorities and institutes, and biopharmaceutical companies are focusing on remedies to treat the patients and control the infection spread. Increasing every day, 450+ potential therapeutic candidates are under investigation. While two-thirds of the pipeline account for therapeutic drugs, the remaining one-third accounts for vaccines.
Of the confirmed active vaccine candidates, nearly 70% are being developed by private/industry developers, with the remaining 30% of projects being led by the academic, public sector and other non-profit organizations. Most COVID-19 vaccine development activity is in North America, with around 36 (46%) developers of the confirmed active vaccine candidates. China constitutes 18% with 14 developers, while, Asia excluding China and Europe also constitute 18% each with 14 developers in each region, respectively.
The long and costly drug development process is anticipated to limit the growth of the COVID-19 vaccine & therapeutics. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), the average cost of research and development of a new drug is approximately $2.6 billion. Moreover, the stringent regulations imposed by the various regulatory authorities such as European Medicines Agency and the US Food and Drug Administration (FDA) in regards with clinical trials during the COVID-19 outbreak attributing to the safety of trial participants, maintaining compliance with good clinical practice, and minimizing risks to trial integrity is a major challenge faced by the COVID-19 vaccine and therapeutics market.
The compounds and medications that are under investigation can be grouped into three broad categories - antivirals, immune-system based, and vaccines. The anti-virals including Darunavir, Favipiravir, Hydroxychloroquine and chloroquine, Lopinavir, and Remdesivir (GS-5734), immune system-related therapies including Tocilizumab, Tocilizumab, and Vitamin C, and other medications are currently being evaluated as therapies. Three key drugs are currently in phase III, of which are two small molecule-based drugs, Remdesivir by Gilead Sciences Inc. and Favipiravir by Fujifilm Toyama Chemical Co Ltd, and Sarilumab, a monoclonal antibody by Regeneron Pharmaceutical. With regards to the prophylactic vaccine pipeline, more than 90% are in early-stage development (discovery and preclinical), and only three in Phase II. These three COVID-19 vaccines are being developed by Sinovac Biotech Ltd, the University of Oxford, and the third vaccine, named CIGB-2020, is being developed by the Center for Genetic Engineering and Biotechnology.
According to the European Centre for Disease Prevention and Control, worldwide, there are over 10.8 million cases of COVID-19. Globally, R&D spending has increased to find a potential drug or vaccine to combat this pandemic. Currently, there is no approved targeted therapy for patients with COVID-19. However, an array of drugs approved for other indications as well as several new investigational drugs are being studied in several hundred clinical trials. The increased R&D spending has contributed to the invention/discovery of more than 400 unique drugs to treat COVID-19 among which 298 are therapeutic drugs and 140 prophylactic vaccines that are spread across all stages of development (Discovery, Preclinical, Phase I, Phase II, and Phase III). As of June 2020, over 2,341 clinical trials are investigating potential therapies for COVID-19, of which nearly 800 are interventional trials.
Other Collaborations:
Key Topics Covered:
1. Executive Summary
2. Disease Overview
2.1. Novel Coronavirus Etiology and Pathogenesis
2.2. Novel Human Coronavirus (ClOVID-19) Clinical Features-Signs and Symptoms
3. Disease Epidemiology and Epidemic Statistics for Major countries
4. Global Pipeline Analysis of COVID-19 Therapeutics and Vaccines
4.1 Global Pipeline Analysis, By Product Type
4.1.1 Small Molecules
4.1.2 Biologics
4.1.2.1 Blood & Plasma Derivatives
4.1.2.2 Monoclonal Antibodies
4.1.2.3 Vaccines
4.1.2.4 Others
4.2 Global Pipeline Analysis, By Phase of development
4.2.1 Preclinical Therapeutics & Vaccines
4.2.2 Clinical Studies
4.2.2.1 Clinical Phase I, II, III
4.3 Global Pipeline Analysis, By Treatment Mechanism & Route of Administration
4.3.1 Mechanism of Action
4.3.1.1 Viral Replication Inhibitors
4.3.1.2 Protease Inhibitors
4.3.1.3 Immunostimulants
4.3.1.4 Other Mechanism of Action
4.3.2 Route of Administration
4.3.2.1 Oral
4.3.2.2 Intravenous
4.3.2.3 Subcutaneous
4.3.2.4 Other Route of Administration
4.4 Global Pipeline Analysis, By Type of Sponsor
4.4.1 Pharma/Biotech Company
4.4.2 Academic Research/Institution
4.4.3 Others such as Government Organizations and CROs
5. Competitive Landscape for Late Stage Therapeutics and Vaccine
5.1 Company Overview
5.2 Product Description
5.3 Research and Development
5.3.1 Non-Clinical Studies
5.3.2 Clinical Studies
5.3.3 Highest/Late Stage Development Activities
5.4 Licensing and Collaboration Agreements
5.5 Milestones & Future Plans
6. Regulatory Framework for COVID-19 Therapeutics and Vaccines Marketing Approvals
6.1 Regulatory Framework in the USA
6.2 Regulatory Framework in EU and Other Countries
7. Recommendations & Conclusion
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/yg3jj7
See the rest here:
COVID-19 Vaccine and Therapeutics Pipeline Analysis Report 2020: The Race to Market as Clinical Trials Move Up a Gear - ResearchAndMarkets.com -...
- Genetic Engineering and Its Applications StudyBullet.com - March 9th, 2025
- The Future of Gene-Editing Treatments for Rare Diseases - March 9th, 2025
- Biotechnology & Genetic Engineering: An Overview - Sciencing - March 9th, 2025
- Hoping to revive mammoths, scientists create 'woolly mice' - NPR - March 9th, 2025
- CRISPR Breakthrough Unlocks the Genetic Blueprint for ... - SciTechDaily - March 9th, 2025
- Mice have been genetically engineered to look like mammoths - The Economist - March 9th, 2025
- Gene modification can create bigger, better tomatoes, but should we do it? - Earth.com - March 9th, 2025
- "Colossal woolly mouse" created by scientists in effort to reconstruct the woolly mammoth - CBS News - March 9th, 2025
- Biotech company hoping to revive woolly mammoth, creates woolly mouse: Study - Straight Arrow News - March 9th, 2025
- Colossal Creates the Colossal Woolly Mouse, Showcasing Breakthroughs in Multiplex Genome Editing and Trait Engineering on the Path to a Mammoth -... - March 9th, 2025
- Colossal Biosciences is one step further in quest to bring back the woolly mammoth - Austin American-Statesman - March 9th, 2025
- Biotech Company Creates 'Woolly Mouse' as a Step in Its Quest to Resurrect Woolly Mammoths Through Gene Editing - Smithsonian Magazine - March 9th, 2025
- 'We didn't know they were going to be this cute': Scientists unveil genetically engineered 'woolly mice' - Livescience.com - March 9th, 2025
- These Genetically Engineered Mice Have Thick Woolly Mammoth Hair - ExtremeTech - March 9th, 2025
- Genetically altered mouse to pave way for resurrection of wolly mammoth? - Hindustan Times - March 9th, 2025
- Turning back the aging clock: Billions of dollars are probably being wasted on genetic manipulation techniques that likely wont work - Genetic... - March 9th, 2025
- OF WOOLLY MICE AND MAMMOTHS - Particle - March 9th, 2025
- Woolly mouse unveiled by firm hoping to bring more extinct animals back to life - The National - March 9th, 2025
- How scientists created woolly mice as part of their quest to bring back the woolly mammoth - The Indian Express - March 9th, 2025
- A Woolly What? - Brownstone Research - March 9th, 2025
- $1 Million Awarded to Continue to Develop Genetically Engineered Stem Cell Products to Fight Gastroesophageal Cancer - PR Newswire - February 15th, 2025
- Engineered animals show new way to fight mercury pollution - EurekAlert - February 15th, 2025
- Genetically modified foods: benefits and applications - Meer - February 15th, 2025
- Genetically modified zebrafish and fruit flies munch on mercury to make it less toxic - Yahoo - February 15th, 2025
- Principles of Genetic Engineering - PubMed Central (PMC) - February 7th, 2025
- The next 'big thing' in genetically modified crops: Drought-tolerant and herbicide resistant wheat. Here's what you need to know - Genetic Literacy... - February 7th, 2025
- Genetic engineering and biotechnology: The future of food is here - Yourweather.co.uk - February 7th, 2025
- Scientists Just Achieved a Major Milestone in Creating Synthetic Life - Yahoo! Voices - February 7th, 2025
- Two males give birth to child in incredible science experiment; the baby is now an adult | Mint - Mint - February 7th, 2025
- Genetic Engineering - The Definitive Guide | Biology Dictionary - January 27th, 2025
- Constitutive expression of Cas9 and rapamycin-inducible Cre recombinase facilitates conditional genome editing in Plasmodium berghei - Nature.com - January 27th, 2025
- What is Genetic Engineering? - Baker Institute - January 27th, 2025
- ARCUS breakthrough: An advanced gene editing tool appears to have cured an infant of an early onset metabolic disorder - Genetic Literacy Project - January 27th, 2025
- Your cells are dying. All the time. - Genetic Literacy Project - January 27th, 2025
- How Genetic Modification is Changing the Future of Conservation - MSN - January 27th, 2025
- Researchers genetically engineer yeast to produce healthy fatty acid - University of Alberta - January 27th, 2025
- genetic engineering summary | Britannica - September 13th, 2024
- The great gene editing debate: can it be safe and ethical? - BBC.com - September 13th, 2024
- Anti-biotechnology campaigners embrace classic crops, are suspicious of hybrid varieties and claim genetic modification violates nature. Heres a... - September 13th, 2024
- Will IL-11 Control Extend Human Life One Day? Early Results are Tantalizing - Securities.io - September 13th, 2024
- Viewpoint: As New Zealand edges toward relaxing its ban on gene edited foods, experts weigh in - Genetic Literacy Project - September 13th, 2024
- Farmers in Brazil and Argentina ramp up growing of genetically-modified drought tolerant wheat that can grow in subtropical regions - Genetic Literacy... - September 13th, 2024
- Scientist explains why we'll never have a real Jurassic Park - and people are crestfallen - indy100 - September 13th, 2024
- Genetic engineering techniques - Wikipedia - January 9th, 2024
- 20.3: Genetic Engineering - Biology LibreTexts - January 9th, 2024
- Genetic engineering - DNA Modification, Cloning, Gene Splicing - December 13th, 2023
- Global Gene Editing Market Poised for Significant Growth, Projected to Reach $14.28 Billion by 2027 - EIN News - December 13th, 2023
- Principles of Genetic Engineering - PMC - National Center for ... - May 17th, 2023
- Quitting: A Life Strategy: The Myth of Perseveranceand How the New Science of Giving Up Can Set You Free - Next Big Idea Club Magazine - May 17th, 2023
- 18 Human Genetic Engineering - Clemson University - March 29th, 2023
- Pros and Cons of Genetic Engineering - Benefits and Risks - March 29th, 2023
- How artificial skin is made and its uses, from treating burns to skin cancer - South China Morning Post - March 29th, 2023
- Genetic Engineering - Meaning, Applications, Advantages and Challenges ... - March 13th, 2023
- Revolutionary Specialty Enzymes Transform Industries, Projected to Reach $2.2 Billion by 2031 - Billion-Dollar - EIN News - March 5th, 2023
- Explained: What is genome editing technology and how is it different from GM technology? - The Indian Express - April 2nd, 2022
- Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference - Yahoo... - April 2nd, 2022
- San Antonio Zoo In Discussions on Woolly Mammoth Project - iHeart - April 2nd, 2022
- Xenotransplantation trials will require adjusting expectations, experts say - STAT - April 2nd, 2022
- 5 Interesting Startup Deals You May Have Missed In March: Restoring The Woolly Mammoth, Faux Seafood And Lots Of Bees - Crunchbase News - April 2nd, 2022
- Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for ... - KULR-TV - April 2nd, 2022
- The Bay Area food tech industry is creating more than vegan burgers. Heres whats next - San Francisco Chronicle - April 2nd, 2022
- Student Startup Teams to Compete For $110000 Cash Prize Pool in U of A's Heartland Challenge - University of Arkansas Newswire - April 2nd, 2022
- Should we test for differences in allergen content between varieties of crops and animal species? - Open Access Government - April 2nd, 2022
- Genetic Engineering - Courses, Subjects, Eligibility ... - December 22nd, 2021
- Scientists Used CRISPR Gene Editing to Choose the Sex of Mouse Pups - Singularity Hub - December 22nd, 2021
- Report calls for broad public deliberation on releasing gene-edited species in the wild - EurekAlert - December 22nd, 2021
- RNA and DNA Extraction Kit Market Study | Know the Post-Pandemic Scenario of the Industry - BioSpace - December 22nd, 2021
- Opinion: Allow Golden Rice to save lives - pnas.org - December 22nd, 2021
- It's time for an alliance of democracies | TheHill - The Hill - December 22nd, 2021
- Aridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against the Omicron variant, other COVID-19... - December 22nd, 2021
- 2021: when the link between the climate and biodiversity crises became clear - The Guardian - December 22nd, 2021
- Wuhan lab leak now the most likely cause of Covid pandemic and the truth WILL come out, experts tell MPs... - The US Sun - December 22nd, 2021
- Biotech ETFs That Outperformed Last Week - Yahoo Finance - December 22nd, 2021
- Human genetic enhancement - Wikipedia - October 5th, 2021
- Viewpoint: Part 1 Opposition stirred by anti-GMO advocacy group propaganda fading in the developing world, as more countries embrace crop... - October 5th, 2021
- Amyris Partners with Inscripta to Enhance Development of Sustainable Ingredients Using the Onyx Genome Engineering Platform - WWNY - October 5th, 2021
- Kingdom Supercultures raises $25m to expand Non GMO suite of microbes to unlock new flavors, textures, and functionalities in food & beverage -... - October 5th, 2021
- Fact check: Genetically engineering your salad with the COVID-19 vaccines? We're not there yet. - USA TODAY - October 5th, 2021
- Making the Transition from an Academic to a Biobusiness Entrepreneur - Genetic Engineering & Biotechnology News - October 5th, 2021
- Is The New York Times Finally 'Learning To Love GMOS'? - American Council on Science and Health - October 5th, 2021